Interojo Co

Interojo Co Net Debt/Equity

The Net Debt to Equity Ratio of Interojo Co (119610.KQ) as of Nov 20, 2026 is 0.20. In the previous year, Net Debt to Equity Ratio was 0.31 — a change of -36.40% (lower).

Net Debt/Equity

0.20

YoY

-36.40%

Last updated:

Net Debt to Equity Ratio of Interojo Co is 2024 0.20 . Net Debt to Equity Ratio of Interojo Co was 2023 0.31 . It decreases by -36.40% lower compared to the previous year.

The Interojo Co Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2017
-0.11 KRW
Jan 1, 2018
-0.08 KRW
Jan 1, 2019
-0.09 KRW
Jan 1, 2020
0.05 KRW
Jan 1, 2021
-0.01 KRW
Jan 1, 2022
0.11 KRW
Jan 1, 2023
0.31 KRW
Jan 1, 2024
0.20 KRW
The Interojo Co Net Debt/Equity history
YEARNet Debt/EquityYoY
0.20-36.40%
0.31+168.16%
0.11-1,426.84%
-0.01-118.27%
0.05-155.18%
-0.09+8.61%
-0.08-30.90%
-0.11-22.37%
-0.15+90.31%
-0.08+2,017.97%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interojo Co Stock analysis

What does Interojo Co do? Interojo Co Ltd manufactures and sells contact lenses including silicone hydrogel lenses, sodium hyaluronate lenses, frequent replacement lenses, conventional lenses, toric lenses, multifocal vision lenses, color lenses, therapy and bandage lenses, and rigid gas permeable (RGP) contact lenses along with solutions. The company distributes its products in domestic and overseas markets, targeting both retail consumers and healthcare providers who purchase lenses for patient use. Its product range caters to diverse vision correction needs, from standard to specialized medical applications, with solutions supporting lens care and usage. The firm's primary revenue streams come from the sale of contact lenses and associated solutions to customers in both domestic and international markets. Products like silicone hydrogel lenses and RGP contact lenses represent key offerings for everyday wear and specialized vision correction, while therapy and bandage lenses serve medical applications requiring professional oversight. The company's domestic market presence complements its overseas distribution, ensuring broad accessibility across different customer segments. Interojo Co Ltd's business model focuses on direct sales of its comprehensive product portfolio to end-users and healthcare institutions. The company's product lines address various vision correction scenarios, from routine daily use with frequent replacement lenses to advanced medical needs with therapy lenses. By maintaining a diverse range of contact lenses and solutions, the company serves both consumer and professional markets without relying on third-party partnerships or additional services. Interojo Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interojo Co stock

Net Debt to Equity Ratio of Interojo Co is 0.20 in 2024.

Net Debt to Equity Ratio of Interojo Co changed from 0.31 to 0.20, representing a -36.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Interojo Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Interojo Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Interojo Co

All Key Metrics — Interojo Co